title: [Tigazon in the therapy of patients with circumscribed scleroderma].
abstract: Therapeutic efficacy of tigason in local scleroderma has been demonstrated in 50 patients. The drug has proved effective at all active stages of the process. Its action is favorable in sclerosis and in deep infiltration foci, when traditional therapy, including cuprenil, are of poor efficacy. Tigason altered the course of the disease, making it more benign. The authors recommend this drug, particularly for patients with intolerance of or resistance to the traditional therapy.
authors.forename: V A
authors.initials: VA
authors.lastname: Samsonov
authors.forename: S A
authors.initials: SA
authors.lastname: Gareginian
mesh_terms: D000328:Adult; D000368:Aged; D001284:Atrophy / Q000188:drug therapy; D002908:Chronic Disease; D004341:Drug Evaluation; D005050:Etretinate / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010859:Pigmentation Disorders / Q000188:drug therapy; D012594:Scleroderma, Localized / Q000188:drug therapy*; D012867:Skin / Q000473:pathology; D013577:Syndrome
chemical_list: D005050:Etretinate
vernacular_title: Tigazon v terapii bol'nykh ogranichennoĭ sklerodermieĭ.